Pharmafit Provence
HYLOVIS LIPO MULTI Emuls oculaire Fl/15ml

TRB Chemedica

HYLOVIS LIPO MULTI Emuls oculaire Fl/15ml

CIP / EAN code: 3760054331020

Product information from VIDAL.

Read the product information
Back to the catalogue

Product information

Find indications, dosage and precautions in the sections below.

Automatic English translation of the French VIDAL document. Original numerical values and units are retained, including decimal commas.

VIDAL
Parapharmacy
Update of 27/01/2026

CE HYLOVIS® LIPO, HYLOVIS® LIPO MULTI eye emulsion
sodium hyaluronate at 0,18 %

Forms and presentations 

Sterile emulsion for topical ophthalmic use:  
  • Hylovis Lipo: Box of 30 single-dose units of 0,4 ml (EAN 3760054331013).
  • Hylovis Lipo Multi: Multi-dose bottle of 15 ml without preservative (EAN 3760054331020).

Composition 

Sodium hyaluronate (0,18 %), triglycerides and phospholipids, lipoic acid, hydroxypropyl methylcellulose, sodium citrate, sodium hydroxide, citric acid, sodium chloride and water for injection. Without preservative agent.

Properties 

Hylovis Lipo and Hylovis Lipo Multi contain sodium hyaluronate, a component naturally present in the eye, which helps protect and hydrate the ocular surface. Thanks to the physical properties of sodium hyaluronate, Hylovis Lipo and Hylovis Lipo Multi have a strong water retention capacity and viscoelastic properties that allow the formation of a lubricating, homogeneous and protective film on the surface of the eye. In this way, it acts on the aqueous layer to hydrate and protect the ocular surface. Hylovis Lipo and Hylovis Lipo Multi are hypo-osmolar in order to compensate for the deleterious phenomena (inflammation) induced by the hyperosmolarity of tears in case of dry eye. Sodium hyaluronate also has mucomimetic properties allowing Hylovis Lipo and Hylovis Lipo Multi to promote anchoring of the tear film. They are without preservative or surfactant in order to optimize local tolerance.

Indications 

Moderate and severe sensations of dry eye.

Directions for use 

Hylovis Lipo and Hylovis Lipo Multi are used by the ocular route. Wash hands thoroughly before instillation. Unless otherwise recommended, instill 1 to 2 drops as often as necessary. After instillation, a few spontaneous eyelid blinks will spread the emulsion evenly over the ocular surface as a transparent and lasting film.
  • Single-dose form: open the sachet and detach one single dose from the strip, taking care to store the other single doses in the original packaging. Always shake the single dose before instillation. Hold the single dose vertically (cap head up) and fully turn the flat part to break the seal. The single dose is open. Tilt the head back and position the tip of the single dose above the eye. Gently pull the lower eyelid downward with the index finger while looking upward, then gently press on the body of the single dose until one drop of Hylovis Lipo is released.
  • Multi-dose form: at first use, unscrew the cap after checking the integrity of the sealed ring on the cap. A small noise is heard corresponding to the tamper-evident ring breaking at the moment of first opening. Always shake the bottle before instillation. Using the index finger, gently pull the lower eyelid downward while looking upward, then squeeze the bottle to instill the drops. Screw the bottle back on with the protective cap after each use.
Hylovis Lipo and Hylovis Lipo Multi are compatible with wearing contact lenses.

Contraindications 

Hypersensitivity to any of the components of the product.

Precautions for use 

Wash hands thoroughly before instillation. Always shake the single dose or bottle before instillation. Avoid contact of the tip of the opened single dose or the tip of the bottle with the hands, eye and eyelids.

If the doctor has prescribed another eye drop, observe an interval of 15 minutes between instillations of the two eye drops.

  • Single-dose form: the single dose must be discarded immediately after use and must not be kept for later instillation. Do not use if the single dose is damaged.
  • Multi-dose form: replace the protective cap after each use while ensuring there is no residual drop on the tip; if necessary, shake it off with a sharp wrist movement. Do not use if the bottle is damaged. Use within 4 months after first opening.

If symptoms persist during use of Hylovis Lipo and Hylovis Lipo Multi, consult a doctor. Keep out of reach and sight of children.

For external use only. Do not swallow.

Store between 2 °C and 25 °C.

Do not use after the expiry date indicated on the box, single dose or bottle.

Adverse effects
In very rare cases, transient disturbances such as slight irritation of the conjunctiva, a foreign body sensation, redness or a burning sensation of the eye, as well as momentarily blurred vision may occur. If an adverse effect persists or is not described in the leaflet, stop using the product and consult a doctor.

ADMINISTRATIVE INFORMATION 

LPPR rate:
3,94 euros (Hylovis Lipo: 30 single doses of 0,4 ml; LPPR code 1167400).
8,75 euros (Hylovis Lipo Multi: 15 ml bottle; LPPR code 1129003).
Recommended price:15,80 euros (Hylovis Lipo: 30 single-dose units of 0,4 ml).
Maximum retail selling price:12,14 euros (Hylovis Lipo Multi: 15 ml bottle).
AAD service code.
Coverage of the sodium hyaluronate ophthalmic emulsion is provided for the symptomatic treatment of dry eye with keratitis or dry keratoconjunctivitis, as third-line therapy after failure of low-viscosity artificial tears and gels.
The prescription must be issued by an ophthalmologist after diagnosis of keratitis or dry keratoconjunctivitis, notably by a colorimetric test performed with a slit lamp. The initial prescription may not exceed 6 months of treatment. At the end of this period, reassessment, ideally by an ophthalmologist, for a possible renewal of the prescription.

Medical device, class IIb CE 0459.
Manufacturer: Horus Pharma, 06700 Saint-Laurent-du-Var.

TRB CHEMEDICA SAS
ArchParc, ActiTech 4
60, avenue Marie-Curie
CS 40218. 74160 Archamps
Tel: 04 50 95 09 00
https://trbchemedica.fr/

Source: VIDAL · Updated on 10/11/2026. This information does not replace advice from a healthcare professional.